In the quarter ended 30 September 2026, Cipla reported a consolidated net profit of ₹878 crore, a 35% decline from ₹1,351 crore earned in the same period of FY26. Global revenues for the quarter stood at ₹7,404 crore, down 2.4% from ₹7,589 crore in Q2 FY26, yet the company achieved a 4% sequential growth QoQ. Earnings before interest, taxes, depreciation and amortisation (EBITDA) slipped 27% YoY to ₹1,388 crore, compared with ₹1,894 crore in the prior year’s quarter. The EBITDA margin contracted to 18.75%, a drop from 24.96% YoY, although it expanded by 200 basis points QoQ to 18.7%.

Cipla’s One-India business recorded its highest quarterly sales, registering a 12% year‑on‑year growth. In North America, the company posted quarterly revenue of $172 million, while the Emerging Markets and Europe segment generated $101 million despite geopolitical uncertainties. The One Africa division saw South Africa’s private market grow 1.3 times faster than the market, with the company’s private business outperforming expectations. Branded Prescription business delivered robust growth, with key therapies outpacing the market, and the US business continued its sequential growth trajectory. The trade generics business delivered strong double‑digit QoQ growth, launching over 15 new products this quarter.

Cipla invested ₹423 crore in research and development during Q2 FY27, representing 5.7% of sales. The investment focused largely on product filings and key development programmes. The company’s net cash position stood at ₹9,823 crore, with debt primarily comprising lease liabilities and working capital requirements. Achin Gupta, MD and Global CEO, highlighted the company’s focus on sustained growth in core businesses, improving productivity, and strengthening the pipeline to serve patients with trusted, high‑quality medicines. He also noted that the North America performance is expected to remain supported by the upcoming product pipeline.

Following the earnings announcement, Cipla shares traded lower on the National Stock Exchange. At 1:30 PM, the shares were at ₹1,336 apiece, down 1.4% from the opening price of ₹1,352.10. The intraday low reached ₹1,334.70, while the day’s high was ₹1,372.70. Over the year, the stock has slipped 12%, fallen 4% over a month, and climbed 0.6% in the past six months. The 52‑week high was ₹1,593.80 on 27 October 2025, and the 52‑week low was ₹1,165.70 on 2 April 2026.

As of 27 October 2026, Cipla’s total market capitalisation was ₹1.08 lakh crore. The company’s performance in Q2 FY27 reflects a mix of revenue growth in certain regions and a decline in profitability metrics. The R&D investment of ₹423 crore underscores Cipla’s commitment to product development, while the net cash position of ₹9,823 crore provides a cushion for future initiatives. The company’s strategic focus on core businesses and pipeline development aims to sustain growth amid competitive pressures.

The earnings report highlighted that the trade generics portfolio remains a key growth driver, with over 15 new launches addressing specific patient needs. Cipla’s One-India and One-Africa segments continue to outperform market expectations, with private market growth in South Africa outpacing the broader market by 1.3 times. The company’s North America revenue of $172 million and Emerging Markets revenue of $101 million demonstrate resilience despite geopolitical uncertainties. Cipla’s management remains optimistic about future performance, citing a robust pipeline and ongoing product development initiatives.